Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design-Reference-Cited by-同舟云学术

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design

Published:2021-06 Issue:6 Volume:205 Page:1612-1621
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Matulay Justin T.¹^ORCID,Li Roger²,Hensley Patrick J.³^ORCID,Brooks Nathan A.³,Narayan Vikram M.⁴^ORCID,Grossman H. Barton³,Navai Neema³^ORCID,Dinney Colin P. N.³^ORCID,Kamat Ashish M.³⁵^ORCID

Affiliation:

1. Department of Urology, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina

2. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida

3. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas

4. Department of Urology, Emory University School of Medicine, Atlanta, Georgia

5. Urologic Oncology (Surgery), Wayne B. Duddlesten Professor of Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial Comment;Journal of Urology;2024-07

2. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder;Journal of Urology;2024-07

3. Bacteria-based cancer therapy: Looking forward;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-07

4. Sequential Intravesical Chemotherapy for Treatment Naïve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls;Urology;2024-06

5. The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis;European Urology Oncology;2024-06